Toggle Nav
Close
  • Menu
  • Setting

CHIR 99021 trihydrochloride

Catalog No.
B5779
A glycogen synthase kinase 3 (GSK-3) inhibitor
Grouped product items
SizePriceStock Qty
5mg
$70.00
In stock
10mg
$105.00
In stock
25mg
$210.00
In stock
100mg
$555.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

CHIR 99021 trihydrochloride is hydrochloride of CHIR 99021, which inhibits GSK-3α and GSK-3β with IC50 values of 10 nM and 6.7 nM. GSK-3 is a serine/threonine kinase, responsible for phosphorylating either the serine or threonine residues of its substrates. This phosphorylation process is involved in various key biological processes, including gene transcription, protein synthesis, cell signaling, cellular transport, proliferation, apoptosis, intracellular communication and glucose regulation. 

References:

1. Ring DB, Johnson KW, Henriksen EJ, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes, 2003, 52(3): 588-595.

2. Pandey MK, DeGrado TR. Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics, 2016, 6(4): 571-593.

3. Mussmann R, Geese M, Harder F, et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. Journal of Biological Chemistry, 2007, 282(16): 12030-12037.

Product Citation

Chemical Properties

Physical AppearanceOff White solid
StorageStore at -20°C
M.Wt574.72
FormulaC22H18Cl2N8·3HCl
Solubilityinsoluble in EtOH; ≥21.87 mg/mL in DMSO; ≥32.45 mg/mL in H2O
Chemical Name(Z)-6-((2-((E)-(4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2(1H)-ylidene)amino)ethyl)imino)-1,6-dihydropyridine-3-carbonitrile trihydrochloride
SDFDownload SDF
Canonical SMILESCC(N1)=CN=C1C(C(C2=C(Cl)C=C(Cl)C=C2)=N/3)=CNC3=N/CC/N=C4C=CC(C#N)=CN/4.Cl.Cl.Cl
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[3]

Cell lines

INS-1E cells

Reaction Conditions

0 ~ 20 μM CHIR 99021 for 24 h incubation

Applications

CHIR 99021 increased the rate of proliferation of INS-1E cells in a dose-dependent manner, with the rate of proliferation reaching a maximum in the presence of 2.5 ~ 10 μM CHIR 99021. Moreover, CHIR 99021 also dose-dependently counteracted INS-1E cell death induced by high glucose and high palmitate.

Animal experiment:[1]

Animal models

Male ZDF rats with type 2 diabetes

Dosage form

16, 30 or 48 mg/kg

Orally

Applications

In ZDF rats with type 2 diabetes, a single oral dose of CHIR 99021 at 30 mg/kg rapidly lowered plasma glucose, with a maximal reduction of nearly 150 mg/dl 3 ~ 4 hours after administration, while plasma insulin remained at or below control levels. Moreover, oral administration of CHIR 99021 at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats substantially improved glucose tolerance, with 14% and 33% reduction in plasma glucose.

Note

The technical data provided above is for reference only.

References:

1. Ring DB, Johnson KW, Henriksen EJ, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes, 2003, 52(3): 588-595.

2. Pandey MK, DeGrado TR. Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging. Theranostics, 2016, 6(4): 571-593.

3. Mussmann R, Geese M, Harder F, et al. Inhibition of GSK3 promotes replication and survival of pancreatic beta cells. Journal of Biological Chemistry, 2007, 282(16): 12030-12037.

Quality Control

Chemical structure

CHIR 99021 trihydrochloride